Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC

MLA

Seock-Ah Im, et al. “Results from the Randomized KEYNOTE-355 Study of Pembrolizumab plus Chemotherapy for Asian Patients with Advanced TNBC.” Npj Breast Cancer, vol. 10, no. 1, Sept. 2024, pp. 1–9. EBSCOhost, https://doi.org/10.1038/s41523-024-00679-7.

APA

Seock-Ah Im, Javier Cortes, David W. Cescon, Mastura Md Yusof, Hiroji Iwata, Norikazu Masuda, Toshimi Takano, Chiun-Sheng Huang, Chi-Feng Chung, Koichiro Tsugawa, Yeon Hee Park, Koji Matsumoto, Kenichi Inoue, Ava Kwong, Sherene Loi, Wei Fu, Wilbur Pan, Vassiliki Karantza, Hope S. Rugo, & Peter Schmid. (2024). Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC. Npj Breast Cancer, 10(1), 1–9. https://doi.org/10.1038/s41523-024-00679-7

Chicago

Seock-Ah Im, Javier Cortes, David W. Cescon, Mastura Md Yusof, Hiroji Iwata, Norikazu Masuda, Toshimi Takano, et al. 2024. “Results from the Randomized KEYNOTE-355 Study of Pembrolizumab plus Chemotherapy for Asian Patients with Advanced TNBC.” Npj Breast Cancer 10 (1): 1–9. doi:10.1038/s41523-024-00679-7.